ରାସାଗିଲିନ

ରାସାଗିଲିନ
Clinical data
Trade names	Azilect, Azipron, others
Synonyms	VP-1012, N-propargyl-1(R)-aminoindan
AHFS/Drugs.com	monograph
MedlinePlus	a606017
data	EU EMA: yes; US FDA: Rasagiline;
Pregnancy; category	AU: B3 ; US: C (Risk not ruled out) ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	36%
Protein binding	88 – 94%
Metabolism	Liver (CYP1A2-mediated)
Elimination half-life	3 hours[ଆଧାର ଲୋଡ଼ା]
Excretion	Kidney and fecal
Identifiers
	IUPAC name (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine;
ECHA InfoCard	100.301.709
Chemical and physical data
Formula	C12H13N
Molar mass	୧୭୧.୨୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C#CCN[C@H]2c1ccccc1CC2;
	InChI InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1 ; Key:RUOKEQAAGRXIBM-GFCCVEGCSA-N ;
(verify)

,

ରାସାଗିଲିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଆଜିଲେକ୍ଟ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପାର୍କିନ୍‌ସନ୍ ରୋଗର ଲକ୍ଷଣମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ଏକାକୀ କିମ୍ବା ଅନ୍ୟ ଔଷଧ ସହିତ ବ୍ୟବହୃତ ହୋଇପାରେ | ^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା, ବଦ‌ହଜମି ଅବସାଦ, ଶୋଇବାରେ ଅସୁବିଧା, ଫୁଲା ଏବଂ ଅଇ ହୋଇପାରେ ।^[୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉଚ୍ଚ ରକ୍ତଚାପ, ସେରୋଟୋନିନ ସିଣ୍ଡ୍ରୋମ, ନିଦ୍ରାଳୁ ଭାବ, ବାଧ୍ୟତାମୂଳକ ଜୁଆ ଖେଳିବାକୁ ଇଚ୍ଛା ଏବଂ ହାଲୁସିନେସନ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୩] ଗର୍ଭଧାରଣ ଏବଂ ସ୍ତନ୍ୟପାନରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ। ^[୪] ଏହା ମୋନୋଆମିନୋ ଅକ୍ସିଡେଜ୍-ବିର ଏକ ଅଣପ୍ରତ୍ୟାବର୍ତ୍ତନକାରୀ ପ୍ରତିବନ୍ଧକ।^[୨]

୧୯୭୯ ମସିହାର ପ୍ରାରମ୍ଭରେ ରାସାଗିଲିନ ବିକଶିତ ହୋଇଥିଲା; ୨୦୦୫ରେ ୟୁରୋପରେ ଏବଂ ୨୦୦୬ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବ‌ହାର ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୫] ^[୨] ^[୬] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୭] ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର 4 ସପ୍ତାହ ଔଷଧର ମୂଲ୍ୟ ପ୍ରାୟ ୨.୫୦ ପାଉଣ୍ଡ ।^[୭]

ଆଧାର

↑ Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (June 2002). "An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells". Neuroscience Letters. 326 (2): 105–8. doi:10.1016/s0304-3940(02)00332-4. PMID 12057839. S2CID 29736753.
1 2 3 4 5 "Rasagiline Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 May 2021. Retrieved 16 October 2021.
1 2 "DailyMed - RASAGILINE MESYLATE tablet". dailymed.nlm.nih.gov. Archived from the original on 28 March 2021. Retrieved 16 October 2021.
↑ "Rasagiline (Azilect) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 24 October 2020. Retrieved 16 October 2021.
↑ "Azilect". Archived from the original on 10 January 2021. Retrieved 16 October 2021.
↑ Stolberg, Victor B. (27 October 2017). ADHD Medications: History, Science, and Issues (in ଇଂରାଜୀ). ABC-CLIO. p. 82. ISBN 978-1-61069-726-2. Archived from the original on 16 October 2021. Retrieved 16 October 2021.
1 2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 446. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[1] Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (June 2002). "An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells". Neuroscience Letters. 326 (2): 105–8. doi:10.1016/s0304-3940(02)00332-4. PMID 12057839. S2CID 29736753.

[AHFS2021-2] 1 2 3 4 5 "Rasagiline Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 May 2021. Retrieved 16 October 2021.

[PI2021-3] 1 2 "DailyMed - RASAGILINE MESYLATE tablet". dailymed.nlm.nih.gov. Archived from the original on 28 March 2021. Retrieved 16 October 2021.

[4] "Rasagiline (Azilect) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 24 October 2020. Retrieved 16 October 2021.

[EPAR2021-5] "Azilect". Archived from the original on 10 January 2021. Retrieved 16 October 2021.

[6] Stolberg, Victor B. (27 October 2017). ADHD Medications: History, Science, and Issues (in ଇଂରାଜୀ). ABC-CLIO. p. 82. ISBN 978-1-61069-726-2. Archived from the original on 16 October 2021. Retrieved 16 October 2021.

[BNF80-7] 1 2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 446. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]